Talaris Therapeutics Incorporated is a late-clinical stage cell therapy company in the U.S. The company is developing a allogeneic, hematopoietic stem cell transplantation method which, if it succeeds, will transform the standard of care for solid organ transplantation and severe autoimmune diseases, as well as for severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, in a Phase II trial for living donor kidney transplant patients. Talaris was founded in 1988 and is headquartered in Louisville, KY.
Name / Ticker | Price | Zen Rating |
---|---|---|
$2.96 | A | |
$8.12 | A | |
$24.28 | A |